News

De novo mutation linked to FA subtype


 

X-ray of the hand of a patient

with Fanconi anemia

Researchers say they have established the cause of a subtype of Fanconi anemia (FA)—a de novo mutation in 1 allele of RAD51, a gene responsible for repairing DNA damage.

The team made this discovery in a child with an FA-like syndrome who has healthy parents and a healthy sister.

“The particular mutation in this patient was a surprise to us,” said Patrick May, PhD, of the University of Luxembourg.

“It occurred only in 1 of the 2 RAD51 gene copies, which every person carries in the genome, but every RAD51 gene copy was normal in the child’s parents.”

Dr May and his colleagues described the mutation in Nature Communications.

Specifically, the researchers found a de novo g.41022153G>A; p.Ala293Thr (NM_002875) missense mutation in 1 allele of RAD51.

They said this heterozygous mutation causes a novel FA subtype, dubbed “FA-R,” which appears to be the first subtype of FA caused by a dominant-negative mutation.

The patient the researchers analyzed has microcephaly and mental retardation but has reached adulthood without the bone marrow failure and pediatric cancers typically observed in patients with FA.

Until this case, researchers believed that mutations leading to FA showed recessive inheritance and therefore had to be derived from both parents to lead to FA. Spontaneous mutations of the RAD51 gene like in this case had not been observed.

Dr May and his colleagues said their finding has implications for genetic counseling of families with a high risk for FA. Previously, people who wanted to have children but had relatives suffering from FA were screened for mutations in 1 of the 17 genes connected with the disease. Now, the risk of having a child with FA has to be recalculated.

“Furthermore, understanding this mutation teaches us more about how the RAD51 gene product protects the DNA and how disruptions of DNA repair may lead to leukemia and solid tumors,” Dr May said. “Of course, understanding the origins of human cancer will help us diagnose it with more confidence earlier and devise new therapies to prevent or mitigate it.”

Recommended Reading

ASH: Prasugrel does not reduce vaso-occlusive crises in sickle cell anemia
MDedge Hematology and Oncology
Video: Eltrombopag boosted standard therapy in severe, newly-diagnosed aplastic anemia
MDedge Hematology and Oncology
Anemia tied to cognitive impairment
MDedge Hematology and Oncology
Myeloma drug could treat sickle cell disease, team says
MDedge Hematology and Oncology
Antiplatelet agent proves ineffective in SCD
MDedge Hematology and Oncology
Statin may reduce vaso-occlusive pain in SCD
MDedge Hematology and Oncology
Graft source and timing of HSCT affect survival in SCD
MDedge Hematology and Oncology
SAA patients benefit from upfront eltrombopag combo
MDedge Hematology and Oncology
HU noninferior to transfusion for stroke prevention in SCD
MDedge Hematology and Oncology
mAb could provide targeted approach to HLH treatment
MDedge Hematology and Oncology